Business Context and Reporting Period
This Form 8-K is filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on March 10, 2021. The filing serves to announce the company's earnings results for the quarter and full year ended December 31, 2020, and to disclose a corporate investor presentation made available on the company's website.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data points. It references an attached press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) for details on:
- Revenue
- Profit and margins
- Cash flow
- Debt and liquidity
Note: The filing text does not provide clear values for these metrics.
Material Changes
The filing text does not explicitly detail material changes versus prior periods. It indicates that such information is contained within the attached press release and presentation exhibits.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure regarding a corporate presentation, which typically contains management commentary and outlook. However, the specific guidance, risks, contingencies, or unusual items are not described in the text of this Form 8-K.
Investor Verification Checklist
- Verify the actual financial results (revenue, net income, cash flow) in the attached Exhibit 99.1 (Press Release).
- Review the Exhibit 99.2 (Investor Presentation) for forward-looking guidance and strategic updates.
- Confirm the company name is ChromaDex Corporation (Ticker: CDXC), as the input metadata incorrectly listed "Niagen Bioscience, Inc."
- Check the Nasdaq Capital Market listing status for the common stock.